Value of Genetic Counseling and Testing for Patients Who Would Like to Know More About Their Personal Risk of AMD
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Cardiology, Ocular |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Ophthalmology |
| Healthy: | No |
| Age Range: | 20 - 59 |
| Updated: | 5/11/2018 |
| Start Date: | March 2016 |
| End Date: | March 2020 |
The goals of this study are:
To assess the impact of genetic testing based on how it alters behaviors, to assess the
utility of serum biomarker measurement in combination with genetic testing, to assess the
utility of genetic counseling in personal analysis of risk for age-related macular
degeneration (AMD), and to assess the impact of presymptomatic genetic testing for choroidal
neovascularization (CNV).
To assess the impact of genetic testing based on how it alters behaviors, to assess the
utility of serum biomarker measurement in combination with genetic testing, to assess the
utility of genetic counseling in personal analysis of risk for age-related macular
degeneration (AMD), and to assess the impact of presymptomatic genetic testing for choroidal
neovascularization (CNV).
Inclusion Criteria:
- Caucasian (this particular genetic test is only validated in Caucasians) Participants
can have a positive family history of AMD but this is not necessary.
Exclusion Criteria:
- Individuals with a personal history of AMD are not eligible. Non-caucasian individuals
are not eligible. Employees of the Moran Eye Center are not eligible.
We found this trial at
1
site
Click here to add this to my saved trials
